Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 81 | ECE2022 | Next issue

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

Card image cap
The 24th European Congress of Endocrinology (ECE) and the Italian Society of Endocrinology look forward to welcoming you to Milan. ECE 2022 returns for a four day, six parallel session festival of endocrine science. You can join us In person in Milan, Italy OR Live @Home online!

Rapid Communications

Rapid Communications 4: Pituitary and Neuroendocrinology 1

ea0081rc4.1 | Rapid Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Immunotherapy in a non-functioning metastatic pituitary neuroendocrine tumor. An encouraging case report

Feola Tiziana , Gianno Francesca , Verrico Monica , Giangaspero Felice , Tomao Silverio , Colonnese Claudio , Esposito Vincenzo , Isidori Andrea , Minniti Giuseppe , Jaffrain-Rea Marie-Lise

Introduction: Metastatic pituitary neuroendocrine tumors (PitNETs) or pituitary carcinomas are rare and challenging conditions. We present a recent and encouraging observation of a temozolomide (TMZ)-resistant clinically non-functioning metastatic PitNET showing a remarkable response to the anti-PDL1 drug Pembrolizumab.Case presentation: A 57-years-old man had transsphenoidal surgery in November 2012 for a large non-functioning intra/suprasellar mass rev...

ea0081rc4.2 | Rapid Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Macro-GH – a novel clinical entity causing a diagnostic challenge – a case report

Stelmachowska-Banas Maria , Ostrowska Magdalena , Goszczyński Tomasz , Kowalski Konrad , Korbonits Marta , Kapuścińska Renata , Zgliczyński Wojciech , Glinicki Piotr

Introduction: Hormone macromolecules are complexes of hormones with other compounds, most often with IgG immunoglobulin. They show variable immunoreactivity in immunochemical tests (IRMA, ELISA, CLIA, ECLIA) and usually have a weak biological effect. They can interfere with immunological assays of various hormones. Some known hormone macrocomplexes are: BB-PRL (24% - 34%), macro-TSH (0.6% - 1.2%) and very rare macromolecules of various hormones: calcitonin, PTH, insulin (singl...

ea0081rc4.3 | Rapid Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Pre-treatment GH levels and number of therapeutic interventions for acromegaly management are predictive of altered MRI bone shape and severity of arthropathy in acromegaly

Kyriakakis Nikolaos , Bowes Michael , Lynch Julie , Kingsbury Sarah R , M Orme Steve , Murray Robert D , Conaghan Philip G

Introduction: Emerging research in 3D-bone shape has provided new insights into the pathogenesis of osteoarthritis (OA). OA patients have increased subchondral bone area, associated with higher prevalence of cartilage loss. Higher B-score, a novel, machine learning-derived OA bone biomarker, is associated with increased OA symptom severity and structural progression. Arthropathy, despite being the commonest cause of morbidity amongst acromegaly patients, remains one of the und...

ea0081rc4.4 | Rapid Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

KLB gene mutations - a rare cause of hypogonadotropic hypogonadism

Cidade-Rodrigues Catarina , Chaves Catarina , Cunha Filipe , Martinho Mariana , Almeida Margarida

Introduction: Congenital hypogonadotropic hypogonadism (CHH) is a rare disease. Mutations in various genes have been implicated in its pathophysiology, the most frequent being ANOS1, FGFR1 and GNRHR genes. FGFR1 is essential for cell proliferation, differentiation and migration during embryonic development and is involved in GnRH neuron development and maintenance. Klotho-beta protein (KLB) is expressed in the postnatal hypothalamus and is t...

ea0081rc4.5 | Rapid Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Validation of the ICD-codes for acromegaly – strategies to reduce false positive cases and improve estimation of the incidence in Sweden

Tsatsaris Erika , Robert Jonas , Berinder Katarina , Bonelli Lorenza , Burman Pia , Dahlqvist Per , Hoybye Charlotte , Ragnarsson Oskar , Vouzouneraki Konstantina , AEkerman Anna-Karin , Ekman Bertil , Eden Engstrom Britt

Purpose: We aimed to validate the diagnosis and estimated national incidence of acromegaly reported in the Swedish National Patient Register (NPR), based on clinically reported International Classification of Diseases (ICD-codes), in comparison with the Swedish Pituitary Register (SPR).Methods: All patients in NPR or SPR between 1991-2018 with the ICD-9 or ICD-10 diagnosis of acromegaly and age >18 years at diagnosis were included. The diagnosis was ...

ea0081rc4.6 | Rapid Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Impact of diabetes on morbidity and mortality in patients with acromegaly

Esposito Daniela , Olsson Daniel S , Franzen Stefan , Gudbjornsdottir Soffia , Miftaraj Mervete , Natman Jonatan , Svensson Ann-Marie , Johannsson Gudmundur

Background: Diabetes is an important risk factor for cardiovascular morbidity and mortality but its impact on outcome in acromegaly is unknown.Methods: This was a nationwide, observational, matched-cohort study. Adult patients with acromegaly due to a pituitary adenoma were identified in the Swedish National Patient Registry between 1987 and 2020 and those with coexistent type 2 diabetes in the National Diabetes Registry and Drug Registry. Overall mortal...

ea0081rc4.7 | Rapid Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

The burden of pain in patients with acromegaly

Kreitschmann-Andermahr Ilonka , Kahl Annalena , Deutschbein Timo , Honegger Jurgen , Unger Nicole , Detomas Mario , Giese Sabrina , Schroeder Bernadette , Chmielewski Witold , Siegel Sonja

Introduction: The aim of the present study was to explore pain prevalence, pain locations and its impact on everyday activities and health-related quality of life (QoL) in a large cohort of patients with acromegaly.Methods: We conducted a survey at three major centers specialized on the treatment of pituitary diseases. 124 patients with acromegaly (mean age 56.6y ± 13.5) filled in a self-constructed questionnaire on acromegaly symptoms, pain includi...

ea0081rc4.8 | Rapid Communications 4: Pituitary and Neuroendocrinology 1 | ECE2022

Impaired insulin secretion without changes in insulin sensitivity explains hyperglycemia in patients with acromegaly treated by pasireotide LAR

Wolf Peter , Dormoy Alexandre , Maione Luigi , Salenave Sylvie , Young Jacques , Kamenicky Peter , Chanson Philippe

Background: Pasireotide is a second line treatment for acromegaly. Besides the growth hormone (GH) lowering efficacy, clinical use is limited by side effects on glycemic control. The aim of this study was to evaluate longitudinal changes in beta-cell function and insulin sensitivity induced by pasireotide therapy in patients with acromegaly.Methods: We performed a retrospective study in 33 patients. Efficacy (GH and IGF-I concentrations; tumor size) and ...